• Mashup Score: 0

    In this second article of the ‘Amyloidosis Series’, we will discuss the prognosis and risk stratification models for AL amyloidosis and summarize the best current practices for patient evaluation.

    Tweet Tweets with this article
    • The @MM_Hub is reviewing the management and treatment of AL #amyloidosis. In the 2nd article of this #EditorialTheme, you can check the staging systems and new prognostic #biomarkers being studied for AL amyloidosis #isa2020 #ash20 #mmsm #hematology https://t.co/4LJEuPqGS9

  • Mashup Score: 0

    Systemic light-chain (AL) amyloidosis is a multi-system disease and therefore can implicate a large variety of organ systems. COVID-19 is…

    Tweet Tweets with this article
    • VIDEO: AL amyloidosis during the pandemic w/ Efstathios Kastritis of @uoaofficial: https://t.co/7ITU6FuoEi #ISA2020 #HemOnc #Amyloidosis #COVID-19 https://t.co/IxD8bI9xxZ

  • Mashup Score: 0

    Autologous stem cell transplant (ASCT) has been utilized in the management of immunoglobulin light chain (AL) amyloidosis for several decades….

    Tweet Tweets with this article
    • VIDEO: Auto-HSCT in AL amyloidosis w/ Eli Muchtar of @MayoClinic: https://t.co/RCb3XswiDL #ISA2020 #HemOnc #Amyloidosis #BMTsm #ImmunoOnc

  • Mashup Score: 1

    The Phase III ANDROMEDA (NCT03201965) study investigated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) for patients with…

    Tweet Tweets with this article
    • VIDEO: ANDROMEDA study: updated safety run-in results w/ @vsanchorawala of @BUMedicine: https://t.co/g8R3TtPxBc #ISA2020 #HemOnc #Amyloidosis #TrialUpdate #CTsm #ImmunoOnc